Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > ARCHIVE
ARCHIVE
- Seminar
December 4, 2006
- Chugai, GSK Working to Ensure Stable Supply of Anti-flu Drugs
December 4, 2006
- MEDICAL DEVICE NEWS IN BRIEF
December 4, 2006
- BUSINESS NEWS IN BRIEF
December 4, 2006
- OPINION
December 4, 2006
- Taiyo Yakuhin to Do More Business with Multiregional Wholesalers
December 4, 2006
- JMA Confirms Opposition to Insurance Deductible System, Flat Sum Payment for Elderly
December 4, 2006
- 4 Major GE Houses Report Growth in Semiannual Sales, Profits
December 4, 2006
- Improve Healthcare for Elderly Using Consumption Tax: Mr Takemi
December 4, 2006
- Chuikyo Recommends NHI Prices for 17 New Products
December 4, 2006
- Prevention Important for Economy Class Syndrome: GSK Seminar
December 4, 2006
- Price Gaps Between Original and GE Drugs Provide Room for Further Cost Curtailment: Council
December 4, 2006
- Alfresa HD: Reinforced Marketing System Contributes to Strong Growth
December 4, 2006
- Companies Should Be Given Greater Freedom in Pricing New Drugs: Dr Aoki
December 4, 2006
- Industry Exchanges Opinions with Vice Minister of Health
December 4, 2006
- FJPWA Seminar
December 4, 2006
- Mediceo Paltac Holdings Aims for SGA Cost Ratio Below 6%: Mr Kumakura
December 4, 2006
- Drug Wholesaler Business Seminar
December 4, 2006
- Sawai May Consider Comprehensive Alliance with New Drug Makers
November 27, 2006
- Towa Pharmaceutical: Sales Rise 12.2% to \13,324 Mil.
November 27, 2006
ページ
Japan’s pharmaceutical policy appears to be entering a new phase. The government’s newly approved honebuto policy and growth strategy both…
A few weeks ago, I had coffee with a very talented executive. Let’s call him Kenji. He has a great job, a big salary, and a solid team. But he was unhappy. He felt bored and wanted a new challenge.…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…